MedTrace Logo

Monıtorıng Glucocortıcoıd Treatment In Patıents Followed In Rheumatology Clınıc

NCT05292456 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-08-03

No results posted yet for this study

Summary

Hypothesis 1: A reduction in side effects is achieved with monitoring glucocorticoid treatment by using the Glucocorticoid Toxicity Index (GTI) in patients using glucocorticoids.

Hypothesis 2: Monitoring treatment by using GTI in patients using glucocorticoids causes a decrease in glucocorticoid toxicity and an increase in the quality of life of patients.

Hypothesis 3: With the involvement of the clinical pharmacist in the multidisciplinary team in patients using glucocorticoids, the drug-related problems of the patients are detected and prevented.

The aim of this study was to evaluate the glucocorticoid treatment of patients with RA, SLE and vasculitis treated with glucocorticoids prospectively by a multidisciplinary team with GTI. In addition, it was aimed to identify and prevent drug-related problems by reviewing all drugs used in these patients by the clinical pharmacist.

Conditions

Sponsors & Collaborators

  • Hacettepe University

    lead OTHER

Principal Investigators

  • Omer Karadag, prof. doctor · Hacettepe University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology,

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-08-31
Completion
2022-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05292456 on ClinicalTrials.gov